Table 3.
Summary DLQI and pruritus VAS scores at week 16
|
Patient-reported outcome |
Placebo (n=88) |
Apremilast BID |
||
|---|---|---|---|---|
| 10 mg (n=89) | 20 mg (n=86) | 30 mg (n=88) | ||
| DLQI |
|
|
|
|
| Baseline |
10.7 ± 6.7 |
10.8 ± 6.3 |
11.6 ± 7.0 |
10.6 ± 6.2 |
| Week 16 |
8.6 ± 7.6 |
7.6 ± 6.3 |
5.8 ± 6.0 |
6.0 ± 6.2 |
| Change from baseline |
−1.9 ± 5.2 |
−3.2 ± 6.0 |
−5.9 ± 6.7* |
−4.4 ± 5.1* |
| Pruritus VAS |
|
|
|
|
| Baseline |
55.5 ± 25.5 |
54.1 ± 23.5 |
58.3 ± 26.7 |
55.3 ± 25.5 |
| Week 16 |
45.6 ± 30.2 |
39.0 ± 27.8 |
35.2 ± 29.2 |
31.6 ± 30.0 |
| Percent change from baseline | −6.1 ± 76.4 | −10.2 ± 100.8 | −35.5 ± 66.0* | −43.7 ± 46.8* |
*P≤0.005 vs placebo.
Values are mean ± SD. DLQI, Dermatology Life Quality Index; VAS, visual analog scale.